References
- Nielsen O H, Andreason B, Bondesen S. Pregnancy in ulcerative colitis. Scand J Gastroent 1983; 18: 735–42
- Willoughby C P, Truelove S C. Ulcerative colitis and pregnancy. Gut 1980; 21: 469–74
- Das K M, Eastwood M A, McManus J PA, Sircus W. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in in-patients. Gut 1973; 14: 631–6
- Das K M, Eastwood M A, McManus J PA, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973; 289: 491–3
- Dew M J, Harries A D, Evans B K, Rhodes J. Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take sulphasalazine. Lancet 1983; ii: 801
- Van Hees P A, Bakker J H, van Tongeren J HM. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with ideopathic proctitis: A study to determine the active therapeutic moiety of sulfasalazine. Gut 1980; 21: 632–5
- Azad Khan A K, Piris J, Truelove S C. An experiment to determine the therapeutic active moiety of sulphasalazine. Lancet 1977; ii: 892–5
- Willoughby C P, Aronson K K, Agback H, et al. Distribution and metabolism in healthy volunteers of disodium azo-diasalicylate, a potential therapeutic agent for ulce rative colitis. Gut 1982; 23: 1081–7
- Rasmussen S N, Bondesen S, Hvidberg E F, et al. 5-amino-salicylic acid in a slow-release preparation: Bioavailability, plasma level and excretion in humans. Gastroenterology 1982; 83: 1062–70
- Klotz U, Maier K E, Fischer C, Bauer K H. A new slow release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Arzneim-Forsch Drug Res 1985; 35: 636–9
- Bondesen S, Rasmussen S N, Rask-Madsen J, et al. 5-amino-salicylic acid in the treatment of inflammatory boweldisease. A review. Acta Med Scand 1987, in press
- Azad Khan A K, Truelove S C. Placental and mammary transfer of sulphasalazine. Br Med J 1979; ii: 1553
- Jasrnerot G, Into-Malmbert M B, Esbjomer E. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scand J Gastroent 1981; 16: 693–7
- Berlin C M, jr., Yaffe S J. Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk. Dev Pharmacol Ther 1980; I: 31–9
- Hansen S H. Assay of 5-aminosalicylic acid and its acetylated metabolite in biological fluids by high performance liquid chromatography on dynamically modified silica. J Chromatogr 1981; 226: 504–9
- Bondesen S, Nielsen O H, Schou J B, et al. Steady state kinetics of 5-aminosalicylic acid and sulphapyridine during sulphasalazine prophylaxis in ulcerative colitis. Scand J Gastroent 1986; 21: 693–700
- Briggs G G., Freeman R K, Yaffe S J. Drugs in Pregnancy and Lactation: Sulfasalazine. Williams & Wilkins, Baltimore 1984; 416–8
- Meese C O, Fischer C, Klotz U. Is N-acetylation of 5 aminosalicylic acid reversible in man. Br J Clin Pharmacol 1984; 18: 612–5
- Lauritsen K, Hansen J, Ryde M, Rask-Madsen J. Colonic azodiasalicylate metaboiism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology 1984; 86: 1496–1500
- Wilson J T, Brown R D, Cherek D R, et al. Drug excretion in human breast milk: Principles, pharmacokinetics and projected consequences. Clin Pharmacokin 1980; 5: 1–66